Orion Pharma: Drug to treat prostate cancer

2020 | Orion Pharma

The innovation for which the prize was awarded this year is Orion Pharma’s drug for the treatment of non-metastatic castration-resistant prostate cancer. Darolutamide, a molecule with a new structure developed by in co-operation Orion Pharma and Bayer, is a response to the need to find new ways to treat prostate cancer. Prostate cancer is the second most common cancer among men worldwide.